Creative Planning Decreases Stock Position in Lantheus Holdings, Inc. $LNTH

Creative Planning decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 27.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 23,027 shares of the medical equipment provider’s stock after selling 8,751 shares during the period. Creative Planning’s holdings in Lantheus were worth $1,885,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of LNTH. Quarry LP grew its position in Lantheus by 2,350.0% during the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 470 shares during the last quarter. Parkside Financial Bank & Trust lifted its stake in shares of Lantheus by 20.2% during the second quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock worth $103,000 after buying an additional 212 shares during the period. AlphaQuest LLC grew its holdings in shares of Lantheus by 252.5% during the first quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock valued at $161,000 after buying an additional 1,184 shares during the last quarter. Bayforest Capital Ltd acquired a new position in shares of Lantheus in the 1st quarter valued at $180,000. Finally, Klein Pavlis & Peasley Financial Inc. purchased a new position in Lantheus in the 1st quarter worth $222,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Down 0.5%

Lantheus stock opened at $58.75 on Thursday. The firm has a market cap of $3.90 billion, a PE ratio of 15.63 and a beta of 0.04. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29. The stock’s 50 day simple moving average is $54.28 and its two-hundred day simple moving average is $64.44. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm had revenue of $92.51 million during the quarter. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Ratings Changes

LNTH has been the topic of several research analyst reports. Truist Financial reiterated a “hold” rating and set a $61.00 price target (down previously from $63.00) on shares of Lantheus in a research note on Monday, November 10th. JMP Securities dropped their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th. The Goldman Sachs Group set a $77.00 price target on shares of Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Mizuho dropped their price objective on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. Finally, B. Riley cut their price objective on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lantheus presently has an average rating of “Hold” and a consensus price target of $74.17.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.